|
Executive Summary: Plasma p‑tau231 as a Precise Early Biomarker for Alzheimer’s Disease
hits:21 Date:11/06/26
This document reviews the scientific rationale, detection technology, clinical performance, and supporting reagents for plasma phosphorylated tau231 (p‑tau231) as a superior early biomarker for Alzheimer’s disease (AD).
1. Clinical Need for Early AD Biomarkers
AD pathology develops decades before symptoms appear. Traditional CSF testing is invasive, and PET imaging is expensive. There is an urgent demand for non‑invasive, blood‑based biomarkers for large‑scale screening and early intervention.
2. Why p‑tau231 Is a Promising Early Marker
Phosphorylation at threonine‐231 occurs earlier than p‑tau181 and p‑tau217 in AD pathogenesis.
p‑tau231 increases shortly after Aβ plaque deposition, making it ideal for preclinical and very early AD detection.
Its concentration in blood is extremely low, requiring ultrasensitive detection methods.
3. Ultrasensitive Detection Technology
Accurate quantification relies on Simoa single‑molecule array digital immunoassay, which delivers >1000× higher sensitivity than conventional ELISA. The assay uses a highly specific anti–p‑tau231 antibody pair to achieve a quantification limit of 0.25 pg/mL in plasma.
4. Diagnostic Performance of Plasma p‑tau231
Strongly differentiates AD from healthy controls, MCI, and non‑AD neurodegenerative diseases.
Significantly correlates with CSF p‑tau231 and Aβ‐PET pathology.
Levels rise with Braak tau staging and decline in cognitive function.
5. Key Advantage Over p‑tau181
Plasma p‑tau231 is elevated earlier in disease:
Abnormal in Aβ‐positive but cognitively normal individuals.
Detectable at Braak stages I–II, whereas p‑tau181 increases only at stages III–IV.
Changes appear earlier in longitudinal progression.
6. Critical Role of p‑tau231 Antibodies
Highly specific anti–p‑tau231 antibodies are foundational for:
Developing ultrasensitive immunoassays (Simoa, ELISA).
Validating biomarker performance in clinical cohorts.
Enabling clinical translation of blood‐based detection kits.
7. Supporting Product from ANT BIO PTE. LTD.
Tau (phospho T231) Mouse Monoclonal Antibody (Cat. No. S0B3220)
High specificity for p‑tau231; no cross‑reactivity with other phospho‑sites.
Validated for WB, IHC, IF, and ELISA kit development.
Supports AD early diagnosis, pathological research, drug screening, and model validation.
Conclusion
Plasma p‑tau231 is a more sensitive and temporally early biomarker than conventional p‑tau markers. With ultrasensitive detection powered by highly specific antibodies, it enables minimally invasive, cost‑effective, and preclinical AD diagnosis, representing a major advance in neurodegenerative disease research and clinical care.
|
中文
